Zurich Cantonal Bank
KLRS

Zurich Cantonal Bank’s Kalaris Therapeutics KLRS Stock Holding History

Zurich Cantonal Bank’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-57
Closed -$17K – 2858
2021
Q4 		$17K Sell
57
-6
-10% -$2.78K ﹤0.01% 2871
2021
Q3 		$37K Sell
63
-1
-2% -$463 ﹤0.01% 2705
2021
Q2 		$29K Buy
64
+5
+8% +$2.58K ﹤0.01% 2547
2021
Q1 		$32K Buy
+59
New +$49.6K ﹤0.01% 2492

Other funds holding KLRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Zurich Cantonal Bank's KLRS Position: Q1 2022 in Review

Zurich Cantonal Bank sold out of Kalaris Therapeutics (KLRS) in Q1 2022, closing a stake of 57 shares — an estimated $17K sold.

Zurich Cantonal Bank first reported a position in KLRS in Q1 2021 and held it in 4 quarters. The position peaked at $37K in Q3 2021. 84 funds tracked by Wall St. Rank hold KLRS as of Q1 2022.

  • Zurich Cantonal Bank reported no remaining Kalaris Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Zurich Cantonal Bank sold 57 Kalaris Therapeutics shares in Q1 2022, an estimated $17K.
  • Zurich Cantonal Bank first reported a position in Kalaris Therapeutics in Q1 2021 and held it in 4 quarters.
  • Zurich Cantonal Bank's Kalaris Therapeutics position peaked at $37K in Q3 2021.
  • 84 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2022.

Based on Zurich Cantonal Bank's 13F filing for Q1 2022, filed 21 Apr 2022.